RU95104898A
(ru)
*
|
1994-03-31 |
1996-12-27 |
Бристоль-Мейерз Сквибб Компани (US) |
Имидазолсодержащие ингибиторы фарнезид-протеинтрансферазы, способ лечения связанных с ней заболеваний
|
US5523456A
(en)
*
|
1994-09-29 |
1996-06-04 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
WO1996010034A2
(en)
*
|
1994-09-29 |
1996-04-04 |
Merck & Co., Inc. |
Thiol-free inhibitors of farnesyl-protein transferase
|
US5585359A
(en)
*
|
1994-09-29 |
1996-12-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5652257A
(en)
*
|
1994-09-29 |
1997-07-29 |
Merck & Co., Inc. |
Heterocycle-containing inhibitors of farnesyl-protein transferase
|
US5756528A
(en)
*
|
1995-06-06 |
1998-05-26 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5972984A
(en)
*
|
1995-06-06 |
1999-10-26 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
FR2736641B1
(fr)
*
|
1995-07-10 |
1997-08-22 |
Rhone Poulenc Rorer Sa |
Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
|
US5968965A
(en)
*
|
1996-01-30 |
1999-10-19 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5981562A
(en)
*
|
1996-01-30 |
1999-11-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6011029A
(en)
*
|
1996-02-26 |
2000-01-04 |
Bristol-Myers Squibb Company |
Inhibitors of farnesyl protein transferase
|
BR9709354A
(pt)
*
|
1996-05-22 |
1999-08-10 |
Warner Lambert Co |
Inibidores de proteína farnesil transferase
|
US6300501B1
(en)
|
1996-05-22 |
2001-10-09 |
Warner-Lambert Company |
Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
|
PE46999A1
(es)
*
|
1996-12-17 |
1999-05-20 |
Warner Lambert Co |
Inhibidores de cicloalquilo de la enzima farnesiltransferasa de las proteinas
|
FR2757855B1
(fr)
*
|
1996-12-30 |
1999-01-29 |
Rhone Poulenc Rorer Sa |
Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
|
US6013662A
(en)
|
1996-12-30 |
2000-01-11 |
Rhone-Poulenc Rorer S.A. |
Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
|
US6124465A
(en)
*
|
1997-11-25 |
2000-09-26 |
Rhone-Poulenc S.A. |
Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
|
US6423689B1
(en)
|
1997-12-22 |
2002-07-23 |
Warner-Lambert Company |
Peptidyl calcium channel blockers
|
WO1999043658A1
(en)
|
1998-02-27 |
1999-09-02 |
Warner-Lambert Company |
Heterocyclic substituted aniline calcium channel blockers
|
US6166052A
(en)
|
1998-03-11 |
2000-12-26 |
Warner-Lambert Company |
Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
|
MXPA00009619A
(es)
|
1998-04-02 |
2006-03-09 |
Targacept Inc |
Composiciones farmaceuticas y metodos de uso.
|
BR9909961A
(pt)
|
1998-04-27 |
2000-12-26 |
Warner Lambert Co |
Derivados de cadeia lateral alquila e alquenila funcionalizados de glicinamidas como inibidores de farnesil transferase
|
AU772575B2
(en)
*
|
1998-12-10 |
2004-04-29 |
F. Hoffmann-La Roche Ag |
Procollagen C-proteinase inhibitors
|
US20010031771A1
(en)
|
1999-05-24 |
2001-10-18 |
Gary Maurice Dull |
Pharmaceutical compositions and methods for use
|
FR2796641B1
(fr)
|
1999-07-22 |
2001-09-21 |
Aventis Pharma Sa |
Nouveau procede de preparation de composes benzoperhydroisoindole
|
WO2005044780A1
(ja)
*
|
2003-11-10 |
2005-05-19 |
Kyorin Pharmaceutical Co., Ltd. |
アミノカルボン酸誘導体とその付加塩及びs1p受容体調節剤
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
TW200813039A
(en)
|
2006-04-19 |
2008-03-16 |
Novartis Ag |
6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
|
CA2664113C
(en)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
PL2109608T3
(pl)
|
2007-01-10 |
2011-08-31 |
Msd Italia Srl |
Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
|
WO2008106692A1
(en)
|
2007-03-01 |
2008-09-04 |
Novartis Vaccines And Diagnostics, Inc. |
Pim kinase inhibitors and methods of their use
|
KR20100017866A
(ko)
|
2007-05-21 |
2010-02-16 |
노파르티스 아게 |
Csf-1r 억제제, 조성물 및 사용 방법
|
CA2690191C
(en)
|
2007-06-27 |
2015-07-28 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
TW200946105A
(en)
|
2008-02-07 |
2009-11-16 |
Kyorin Seiyaku Kk |
Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
BR112012008849A2
(pt)
|
2009-10-14 |
2015-09-22 |
Schering Corp |
composto, composição farmacêutica, e, uso de um composto
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
CN103080093A
(zh)
|
2010-03-16 |
2013-05-01 |
达纳-法伯癌症研究所公司 |
吲唑化合物及其应用
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
CN103068980B
(zh)
|
2010-08-02 |
2017-04-05 |
瑟纳治疗公司 |
使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
|
SI2606134T1
(sl)
|
2010-08-17 |
2019-08-30 |
Sirna Therapeutics, Inc. |
RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA)
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
IN2013MN02170A
(no)
|
2011-04-21 |
2015-06-12 |
Piramal Entpr Ltd |
|
AU2012329098B2
(en)
|
2011-10-26 |
2017-08-03 |
Allergan, Inc. |
Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
JP6106685B2
(ja)
|
2011-11-17 |
2017-04-05 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
C−jun−n−末端キナーゼ(jnk)の阻害剤
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
JP6280554B2
(ja)
|
2012-09-28 |
2018-02-14 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Erk阻害剤である新規化合物
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
PL2925888T3
(pl)
|
2012-11-28 |
2018-03-30 |
Merck Sharp & Dohme Corp. |
Kompozycje i sposoby do stosowania w leczeniu nowotworów
|
WO2014100065A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
WO2015058140A1
(en)
|
2013-10-18 |
2015-04-23 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
|
EP3057955B1
(en)
|
2013-10-18 |
2018-04-11 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
US10017477B2
(en)
|
2014-04-23 |
2018-07-10 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
US10870651B2
(en)
|
2014-12-23 |
2020-12-22 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
JP6861166B2
(ja)
|
2015-03-27 |
2021-04-21 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
サイクリン依存性キナーゼの阻害剤
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
WO2017044858A2
(en)
|
2015-09-09 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
US10975084B2
(en)
|
2016-10-12 |
2021-04-13 |
Merck Sharp & Dohme Corp. |
KDM5 inhibitors
|
CN110650976B
(zh)
|
2017-04-13 |
2024-04-19 |
赛罗帕私人有限公司 |
抗SIRPα抗体
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
WO2024180169A1
(en)
|
2023-03-02 |
2024-09-06 |
Carcimun Biotech Gmbh |
Means and methods for diagnosing cancer and/or an acute inflammatory disease
|